For US Healthcare Professionals
I am a:
For US Healthcare Professionals
Full Prescribing Information
View TREMFYA® patient before-and-after images by body region
Select Image:
(79% PASI improvement)
Photos are representative of an actual TREMFYA® patient from the VISIBLE study at baseline (Week 0) and Week 16.
Images are Janssen-owned from blinded trial: NCT0572150.
*Individual results may vary.
Reference: 1. Data on file. Janssen Biotech, Inc.
(100% PASI improvement)
Photos are representative of an actual TREMFYA® patient from the VISIBLE study at baseline (Week 0) and Week 16.
Images are Janssen-owned from blinded trial: NCT0572150.
*Individual results may vary.
Reference: 1. Data on file. Janssen Biotech, Inc.
(86% PASI improvement)
Photos are representative of an actual TREMFYA® patient from the VISIBLE study at baseline (Week 0) and Week 16.
Images are Janssen-owned from blinded trial: NCT0572150.
*Individual results may vary.
Reference: 1. Data on file. Janssen Biotech, Inc.
(72% PASI improvement)
Photos are representative of an actual TREMFYA® patient from the VISIBLE study at baseline (Week 0) and Week 16.
Images are Janssen-owned from blinded trial: NCT0572150.
*Individual results may vary.
Reference: 1. Data on file. Janssen Biotech, Inc.
(90% PSSI improvement)
Photos are representative of an actual TREMFYA® patient from the VISIBLE study at baseline (Week 0) and Week 16.
Images are Janssen-owned from blinded trial: NCT0572150.
*Individual results may vary.
Reference: 1. Data on file. Janssen Biotech, Inc.
(100% PSSI improvement)
Photos are representative of an actual TREMFYA® patient from the VISIBLE study at baseline (Week 0) and Week 16.
Images are Janssen-owned from blinded trial: NCT0572150.
*Individual results may vary.
Reference: 1. Data on file. Janssen Biotech, Inc.
Age:
36
BMI:
31.1 kg/m2
Baseline BSA
involvement:
54%
Psoriasis duration:
12 years
Previous therapies:
topicals, biologics
Plaque psoriasis photos are of a real patient from VOYAGE 2 who received TREMFYA® 100 mg at Weeks 0 and 4, then q8w thereafter through Week 48. Other areas affected (not shown) yielded similar results to those depicted here. Clinical photos shown here are from Week 0, Week 16, and Week 48. Photos are for illustrative purposes only and are used with permission from Janssen Biotech, Inc.
*Individual results may vary.
BMI=body mass index; BSA=body surface area.
Reference: 1. Data on file. Janssen Biotech, Inc.
Photos are representative of an actual TREMFYA® patient at baseline (Week 0), Week 4 and Week 16 outside of clinical trials.
*Individual results may vary.
Reference: 1. Data on file. Janssen Biotech, Inc.
(96% PASI improvement)
Photos are representative of an actual TREMFYA® patient from the VISIBLE study at baseline (Week 0) and Week 16.
Images are Janssen-owned from blinded trial: NCT0572150.
*Individual results may vary.
Reference: 1. Data on file. Janssen Biotech, Inc.
(100% PASI improvement)
Photos are representative of an actual TREMFYA® patient from the VISIBLE study at baseline (Week 0) and Week 16.
Images are Janssen-owned from blinded trial: NCT0572150.
*Individual results may vary.
Reference: 1. Data on file. Janssen Biotech, Inc.
